The study findings indicate that AKT inhibitors such as MK-2206, MEK inhibitors like Selumetinib, and BET inhibitors including JQ1 all exert significant effects on CRC treatment (22–24). The gene discussed is AKT1; the disease is colorectal carcinoma.